We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

DIRUI Presents High-End Diagnostic Systems for Hospitals and High-Volume Labs at EUROMEDLAB 2022

By Carolyn Moody, RN - News Editor
Posted on 12 Apr 2022
Print article
Image: DIRUI presented its high-end analyzers at EUROMEDLAB (Photo courtesy of DIRUI)
Image: DIRUI presented its high-end analyzers at EUROMEDLAB (Photo courtesy of DIRUI)

DIRUI Industrial Co., Ltd. (Jilin, China) presented its high-end diagnostic systems, including hematology, chemiluminescence immunoassay, chemistry and urinanalysis analyzers, for hospitals and high-volume labs at EUROMEDLAB 2022.

DIRUI demonstrated its BF-7200Plus automatic hematology analysis system which has a maximum throughput of 480 tests per hour and measures 37 parameters (including RET detection), five scattergrams and two histograms. It performs optical analysis for WBC measurement and comes with pathology and morphology abnormality alarms. DIRUI also demonstrated its new CM180 chemiluminescence immunoassay analyzer with a throughput of up to 180 tests/hour and walk-away time of up to 2.5 hours. The CM180 has time to first result of only 15 minutes and allows 25 items to be tested at the same time. Featuring a user-friendly design to keep test results accurate and reliable, the CM180 analyzer provides the best solution for laboratory chemiluminescence immunoassay.

Also on display at EUROMEDLAB 2022 was DIRUI’s CS-T240Plus automatic chemistry analyzer which offers the ultimate in convenience, performance and confidence for small to medium size laboratories. The powerful desktop analyzer has a maximum throughput of 240 tests/hour at constant speed and 480 tests/hour for ISE. It uses whole blood samples to test for HbA1c, ensuring more accurate results and has a water consumption of only three liters per hour. This automated random access clinical chemistry analyzer can be easily integrated with any type of laboratories for routine, emergency analysis. In addition, DIRUI showcased its MUS-3600 automatic urinanalysis system with a flexible combination of modules and super fast detection speed. It has a throughput of up to 480 tests per hour (for hybrid) and allows up to 580 urine samples to be loaded at one time. Using leading detection methodologies, the MUS-3600 can provide objective and quantitative report information, clear and visible particle image information, and three key clinical information - red blood cell morphology information, urinary tract infection information, and urine culture information.

Related Links:
DIRUI Industrial Co., Ltd. 

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
H.pylori Test
Humasis H.pylori Card
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Sekisui Diagnostics UK Ltd.